| Literature DB >> 27508868 |
Gary D Lopaschuk1, Subodh Verma2.
Abstract
The EMPA-REG OUTCOME trial (Zinman et al., 2015) established cardioprotective effects of empagliflozin in high-risk diabetic patients, but the underlying mechanisms remain elusive. A recent hypothesis proposed that increased ketone oxidation contributed to the effect, but several caveats indicate that the role of myocardial ketone oxidation is far from clear.Entities:
Mesh：
Substances：
Year: 2016 PMID： 27508868 DOI： 10.1016/j.cmet.2016.07.018
Source DB: PubMed Journal: Cell Metab ISSN： 1550-4131 Impact factor: 27.287